NO20060080L - Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer - Google Patents

Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Info

Publication number
NO20060080L
NO20060080L NO20060080A NO20060080A NO20060080L NO 20060080 L NO20060080 L NO 20060080L NO 20060080 A NO20060080 A NO 20060080A NO 20060080 A NO20060080 A NO 20060080A NO 20060080 L NO20060080 L NO 20060080L
Authority
NO
Norway
Prior art keywords
liver
dition
pyrrole
derivatives
receptor modulators
Prior art date
Application number
NO20060080A
Other languages
English (en)
Norwegian (no)
Inventor
Patrik Holm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20060080L publication Critical patent/NO20060080L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20060080A 2003-07-11 2006-01-05 Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer NO20060080L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316237.7A GB0316237D0 (en) 2003-07-11 2003-07-11 Therapeutic agents
PCT/SE2004/001115 WO2005005416A1 (en) 2003-07-11 2004-07-08 Pyrrole-2, 5-dithione derivatives as liver x receptor modulators

Publications (1)

Publication Number Publication Date
NO20060080L true NO20060080L (no) 2006-02-08

Family

ID=27741986

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060080A NO20060080L (no) 2003-07-11 2006-01-05 Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer

Country Status (26)

Country Link
US (1) US20060189663A1 (ja)
EP (1) EP1646625B1 (ja)
JP (1) JP2007521313A (ja)
KR (1) KR20060034284A (ja)
CN (1) CN100478340C (ja)
AR (1) AR045720A1 (ja)
AT (1) ATE399776T1 (ja)
AU (1) AU2004256000B2 (ja)
BR (1) BRPI0412479A (ja)
CA (1) CA2532068A1 (ja)
CO (1) CO5640134A2 (ja)
DE (1) DE602004014772D1 (ja)
ES (1) ES2308205T3 (ja)
GB (1) GB0316237D0 (ja)
HK (1) HK1088318A1 (ja)
IL (1) IL172759A0 (ja)
IS (1) IS8291A (ja)
MX (1) MXPA06000447A (ja)
NO (1) NO20060080L (ja)
RU (1) RU2006102129A (ja)
SA (1) SA04250203B1 (ja)
TW (1) TW200507836A (ja)
UA (1) UA82108C2 (ja)
UY (1) UY28407A1 (ja)
WO (1) WO2005005416A1 (ja)
ZA (1) ZA200600229B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592771A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
SE0500058D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 5
WO2007002654A2 (en) * 2005-06-28 2007-01-04 Daiichi Sankyo Company, Limited. Lxr ligand testing method
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
US20100056444A1 (en) 2006-10-12 2010-03-04 Sven Martin Jacobson Treatment of Alzheimer's Disease Using Compounds that Reduce the Activity of Non Selective Ca Activated ATP- Sensitive Cation Channels Regulated by SUR1 Receptors
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
PT2868315T (pt) 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
WO2009097443A2 (en) * 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
US8492427B2 (en) 2008-07-01 2013-07-23 Genentech, Inc. Isoindolones derivatives as MEK kinase inhibitors and methods of use
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
JP7025022B2 (ja) 2016-01-11 2022-02-24 ザ ロックフェラー ユニバーシティー 骨髄系由来抑制細胞関連障害の治療のための方法
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
KR200492570Y1 (ko) 2018-12-04 2020-11-05 박규환 조립식 계단장치를 위한 발판
JP2023509845A (ja) 2019-12-13 2023-03-10 インスピルナ，インコーポレーテッド 金属塩及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2234300T3 (es) * 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
CA2377999A1 (en) * 1999-07-08 2001-01-18 Tularik Inc Compositions and methods for raising hdl cholesterol levels

Also Published As

Publication number Publication date
TW200507836A (en) 2005-03-01
ZA200600229B (en) 2007-04-25
UY28407A1 (es) 2005-02-28
SA04250203B1 (ar) 2008-02-25
MXPA06000447A (es) 2006-04-07
CO5640134A2 (es) 2006-05-31
GB0316237D0 (en) 2003-08-13
BRPI0412479A (pt) 2006-09-19
ES2308205T3 (es) 2008-12-01
EP1646625A1 (en) 2006-04-19
IL172759A0 (en) 2006-04-10
CN1820003A (zh) 2006-08-16
EP1646625B1 (en) 2008-07-02
ATE399776T1 (de) 2008-07-15
RU2006102129A (ru) 2006-08-27
AR045720A1 (es) 2005-11-09
CN100478340C (zh) 2009-04-15
UA82108C2 (uk) 2008-03-11
CA2532068A1 (en) 2005-01-20
DE602004014772D1 (de) 2008-08-14
WO2005005416A1 (en) 2005-01-20
JP2007521313A (ja) 2007-08-02
HK1088318A1 (en) 2006-11-03
US20060189663A1 (en) 2006-08-24
AU2004256000A1 (en) 2005-01-20
KR20060034284A (ko) 2006-04-21
AU2004256000B2 (en) 2007-07-26
IS8291A (is) 2006-02-09

Similar Documents

Publication Publication Date Title
NO20060080L (no) Pyrrol-2,5-ditionderivater som Lever X reseptormodulatorer
NO20060081L (no) Pyrrol-2,5-dionderivater som lever X reseptormodulatorer
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
NO20055892L (no) Karboksylsyrederivater
WO2007050726A3 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
CN104995176B (zh) 调节bace所介导的app加工的乙内酰脲
NO20073248L (no) Derivater av isotiazol-3(2H)-on 1,1-dioksider som lever X reseptor modulatorer
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
WO2009009501A3 (en) Non-basic melanin concentrating hormone receptor-1 antagonists and methods
BRPI0516237A (pt) derivado de pirimidina fundido com anel não aromático
CN102093246B (zh) 酯类化合物、其制备方法和应用
CN102300562A (zh) 含有2-氧代-1-吡咯烷衍生物的药物组合物
SE0500056D0 (sv) Therapeutic agents 4
SE0500058D0 (sv) Therapeutic agents 5
CN106459016B (zh) 1,1’-(1,6-二氧代-1,6-己二基)双-d-脯氨酸的前药
EP1435353A1 (en) Novel heterocyclic compound and anti-inflammatory agent
EP2412705B1 (en) Novel therapeutic agent for cognitive impairment
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
Ma et al. Straightforward and effective synthesis of γ-aminobutyric acid transporter subtype 2-selective acyl-substituted azaspiro [4.5] decanes
Sauerberg et al. Structure–activity relationships of dimeric PPAR agonists
AU646240B2 (en) 4,4'-{9H-fluoren-9-ylidenebis(methylene)}-bispyrimidine for treating neurological disorders
CN103040779A (zh) 用于神经系统疾病的口服固体药物组合物
CN104523712B (zh) 一种盐酸吡格列酮格列美脲片剂组合物
CN108368095A (zh) 作为sap消耗剂的d-脯氨酸衍生物
CN103788058B (zh) 一种木脂素类化合物及其在防治阿尔茨海默症中的应用

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application